Acerca de

News

Media and Press Releases

Find out what’s new in KRAS - from advances in research and treatment options to announcements about upcoming KRAS Kickers events, programming, and more.

For media inquiries, please contact terri@kraskickers.org

Smiling cancer patient interviews expert Doctor

Essential Guide to Cancer Biomarkers For Cancer Patients

Need to know what mutation is driving the cancer bus. It's different than noise from the back of the bus. Biomarkers testing tells us what to Aim for as the cancer driver, not the background noise. Taking out the cancer driver can make the difference. Biomarkers provide the insights as to what is driving the cancer.

NEW combination trial arm of RMC-9805 plus RMC-6236

Changes to KRAS G12D trial - July 23, 2024 The monotherapy arm of RMC-9805 - RAS(ON) inhibitor now includes info on the combination arm...

Black Diamond trial of BDTX-4933

A Phase 1 Study of BDTX-4933 in Patients With BRAF and Select RAS/MAPK Mutation Positive Cancers Brief Summary: "BDTX-4933-101 is a...

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

" Phase 2 study evaluating the efficacy and immune response to a synthetic long peptide mutant KRAS vaccine (SPL mKRASvax) combined with...

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

PHASE 1 trial: Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS At MD...

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects with Solid Tumors

Phase 1 trial, 230 patients Trial opened April 2024 in Australia Expanded to US Locations in September 2024 “ Brief Summary This is a...

PROSPER trial for KRAS G12C mutations

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors (PROSPER) Phase 1/2 - 403 patients to enroll Opened in...

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

"This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK),...

Evaluation of RMC-6236 in Subjects With Advanced Solid Tumors Harboring Specific Mutations in KRAS

Phase 1 trial Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumors Enrollment into...

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

"Brief Summary Phase 1 study for patients with resected PDAC after neoadjuvant and/ or adjuvant chemotherapy and/or radiation, as well as...

BREAKER-101 trial - Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors

“First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in...

Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic, colorectal and non-small cell lung cancer

ESMO24 abstract 608O - Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in...

Newsletters

Our e-newsletter, Keeping Up with KRAS Kickers, is shared monthly with the community. Check out some recent newsletters to see what we've been up to and what's coming up!